谷氨酰胺与重组人生长激素对肝硬化患者肠黏膜屏障的影响  

Effects of Glutamine and Recombinant Human Growth Hormone on Intestinal Barrier of Patients with Hepatic Cirrhosis

作　　者：刘波[1] 邓宇[1] 许瑞云[1] 

机构地区：[1]中山大学附属第三医院肝胆外科,广东中山510630

出　　处：《医学临床研究》2006年第10期1598-1600,共3页Journal of Clinical Research

摘　　要：【目的】观察Gln与rhGh单独应用或联合应用对肝硬化患者小肠黏膜屏障形态和功能的影响。【方法】20位肝硬化患者随机分成四组,给予等氮等热量营养支持7d,Gln+rhGh组口服Gln(0.3g/kg·d)和皮下注射rhGh(10U/d);Gln组口服Gln;rhGh组应用皮下注射rhGh;对照组应用相应安慰剂。观察治疗前后患者小肠黏膜通透性和十二指肠黏膜绒毛高度和隐窝深度的变化,分别进行比较。【结果】Gln+rhGh组治疗后小肠黏膜通透性有显著性的降低(P<0.05),且显著低于其他三组(P<0.05);十二指肠黏膜绒毛高度和隐窝深度有显著性的增高(P<0.05),且显著高于其他三组(P<0.05)。【结论】Gln与rhGh联合应用能减低肠道黏膜的通透性和维持其形态学的完整。[Objective]To investigate the morphologic and functional alterations in intestinal mucosa of the cirrhotic patients after 7 day＇s applications of Glutamine（Gln） combined with recombinant human growth hormone（rhGh）. [Methods]Twenty patients were randomly allocated to 4 groups, according to grouping , patients daily received oral Gln（0.3g/kg · d） and rhGh （10U/d）, Gln only, rhGh only and placebo only. All patients were restricted to isocaloric and isonitrogenic intakes everyday. Changes in intestinal permeability, villus heights and crypt depths of mucosa in the second part of duodenum were investigated after 7-day＇s trial ,and comparisons were made among groups as well as between before and after the trial in the same group, [Results]In Gln＋rhGh group, post-trial intestinal permeability decreased significantly than that of pre-trial（ P〈0.05） ,and than that in the other 3 groups（ P 〈0. 05） ; villus heights and crypt depths increased significantly than that of pre-trial（ P 〈0.05） ,and than that in the other 3 groups（ P〈0.05）. [Conclusion]Application of Gln combined with rhGh on cirrhotic patients could prevent deterioration of gut permeability, preserve mucosal structure.

关 键 词：肝硬化 肠粘膜 谷氨酰胺 生长激素(人) 

分 类 号：R575.2[医药卫生—消化系统]